Bär & Karrer Ltd. | View firm profile
On 6 December 2019, Kuros Biosciences, a life science company focusing
on the development and marketing of orthobiologics, completed a capital
increase by way of a rights offering to its shareholders. 36.3% of the
shareholders of Kuros Biosciences exercised their subscription rights in the
rights offering. 2,818,718 of the remaining shares not subscribed were
preferably allocated to Optiverder B.V. and further remaining shares were
placed in the market. The offer price was set at CHF 1.95 per share.
Octavian and Helvetische Bank acted as Managers.
Bär & Karrer acted as legal adviser to the Managers in this
transaction. The team included Thomas U. Reutter, Alexander von Jeinsen and
Carlo Hunter (all Capital Markets) as well as Christoph Suter and Martin Leu
(both Tax).